Hodgkin's disease in 82 Turkish children diagnosed over a 10-year period: Epidemiological, clinical, and histopathologic features and prognosis with prolonged chemotherapy

Pediatric Hematology and Oncology

Volumn 14, Issue 4, 1997, Pages 359-366

  Ertem, Ulya ^a,d   Duru, Feride ^a   Daǧdemir, Ayhan ^a   Taçyildiz, Nurdan ^a   Pamir, Ali ^b   Akçayöz, Ayşegül ^a   Uluoǧlu, Ömer ^c   Teziç, Tahsin ^a  

^a DR SAMI ULUS CHILDREN S HOSPITAL   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

^d Asagi Ayranci Yesilyurt Sok No:25/14   (Turkey)

Author keywords

Children; Hodgkin; Turkish

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL FEATURE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; RETROSPECTIVE STUDY; TURKEY (REPUBLIC);

EID: 0030955572     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.3109/08880019709041595     Document Type: Article

References (20)

1. Correa P, O'Conor T. Epidemiologic patterns of Hodgkin's disease. Int J Cancer. 1971;8:192-201.
2. Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med. 1981;304:135-140.
3. Rosenthal J, Ben Arush MW, Kuten A, Ben Arie J, Ben Shahar M, Robinson E. Hodgkin's disease in childhood: treatment modalities, outcome and epidemiological aspects. Am J Pediatr Hematol Oncol. 1994;16:138-142.
4. Zarate-Osorno A, Roman LN, Kingma DW, Meneses-Garcia A, Jaffe ES. Hodgkin's disease in Mexico: prevalence of Epstein-Barr virus sequences and correlation with histopathologic subtype. Cancer. 1995;75:1360-1366.
5. Parkes SE, Coad NAG, Muir KR, Jones TJ, Cameron AH, Mann JR. Hodgkin's disease in children in the West Midlands, 1957-1986: a large population-based study. Pediatr Hematol Oncol. 1994;11:471-486.
6. Riyat MS. Hodgkin's disease in Kenya. Cancer. 1992;69:1047-1051.
7. Levy LM. Hodgkin's disease in black Zimbabweans. Cancer. 1988;61:189-194.
8. Hagemeister FB. Hodgkin's disease: the next decade. Leuk Lymphoma. 1996;21:53-61.
9. Oberlin O, Leverger G, Pacquement H, et al. Low dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol. 1992;10:1602-1608.
10. Behrendt H, Van Bunningen BNFM, Van Leeuwen EF. Treatment of Hodgkin's disease in children with or without radiotherapy. Cancer. 1987;59:1870-1873.
11. Behrendt H, Brinkhuis M, Van Leeuwen EF. Treatment of childhood Hodgkin's disease with ABVD without radiotherapy. Med Pediatr Oncol. 1996;26:244-248.
12. Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD or MOPP alternating with ABVD. N Engl J Med. 1992;327:1478-1484.
13. Ertem U, Duru F, Pamir A, et al. Burkitt's lymphoma in 63 Turkish children diagnosed over a ten year period. Pediatr Hematol Oncol. 1996;13:123-134.
14. Leventhal B, Donaldson S. Hodgkin's disease. In: Pizzo PA, Poplack DG, eds. Principles and Practice of Pediatric Oncology. 2d ed. Philadelphia: Lippincott; 1993:577-595.
15. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patients. Br J Cancer. 1977;35:1-39.
16. Cox DR. Regression models and life tables. J R Stat Soc B. 1972;34:187-202.
17. Pamir A, Çavdar AO, Vonlanthen R, Tinguely M, Borisch B. Epstein-Barr virus latent membrane protein expression and distribution of viral subtypes in Turkish Hodgkin's disease. Med Pediatr Oncol. 1995;25:260.
18. Çavdar AO, Yavuz G, Babacan E, et al. Burkitt's lymphoma in Turkish children: clinical, viral (EBV) and molecular studies. Leuk Lymphoma. 1994;14:323-330.
19. Donaldson SS, Hancock SL. Second cancers after Hodgkin's disease in childhood. N Engl J Med 1996;334:792-794.
20. Donaldson SS, Hancock SL. Late effects of treatment for childhood Hodgkin's disease. N Engl J Med. 1996;335:354-355.